Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Actinium PharmaceuticalsSTU:7AY1 -2.00%25 PB Ratio is 11.47 as of Jul. 28, 2026, which is 353% above its 10-year median of 2.53. GuruFocus rates STU:7AY1 with a GF Score™ of 25/100. The stock has 4 warning signs investors should review. Among 1,228 Biotechnology companies, Actinium Pharmaceuticals ranks worse than 88.93% on this metric.
The historical rank and industry rank for Actinium Pharmaceuticals's PB Ratio or its related term are showing as below:
STU:7AY1'
s PB Ratio Range Over the Past 10 Years
Min: 0.91 Med: 2.53 Max: 17.95
Current: 11.7
During the past 13 years, Actinium Pharmaceuticals's highest PB Ratio was 17.95. The lowest was 0.91. And the median was 2.53.
STU:7AY1's PB Ratio is ranked worse than 88.93% of 1228
companies
in the Biotechnology industry
Industry Median: 2.78
vs STU:7AY1: 11.70
During the past 12 months, Actinium Pharmaceuticals's average Book Value Per Share Growth Rate was -91.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -54.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -39.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -25.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Actinium Pharmaceuticals was 110.40% per year. The lowest was -95.50% per year. And the median was -19.85% per year.
Back to Basics: PB Ratio
Actinium Pharmaceuticals (STU:7AY1) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Actinium Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Actinium Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Actinium Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Actinium Pharmaceuticals (STU:7AY1) has a PB Ratio of 11.47 as of Jul. 28, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Actinium Pharmaceuticals and its competitors. This is 353% above median its historical median of 2.53. Over the past decade, Actinium Pharmaceuticals' PB Ratio has ranged from 0.91 to 17.95. According to the industry distribution chart, Actinium Pharmaceuticals ranks #1092 out of 1228 companies in the Biotechnology industry, placing it in the top 88.9%.
Is Actinium Pharmaceuticals' PB Ratio too high?
Actinium Pharmaceuticals' current PB Ratio of 11.47 is 353% above median its 10-year median of 2.53. Over the past 10 years, this metric has ranged from a low of 0.91 to a high of 17.95. The Biotechnology industry median PB Ratio is 2.78. Actinium Pharmaceuticals' value of 11.47 is 312.6% above this industry median. Based on the distribution chart, Actinium Pharmaceuticals ranks #1092 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Actinium Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Actinium Pharmaceuticals' PB Ratio compare to PSTV and IGC?
According to the Biotechnology industry distribution chart, Actinium Pharmaceuticals ranks #1092 out of 1228 companies for PB Ratio. This places Actinium Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 2.78. Actinium Pharmaceuticals' value of 11.47 is 312.6% above this benchmark. Historically, Actinium Pharmaceuticals' own PB Ratio has ranged from 0.91 to 17.95 over the past decade. While the company's 10-year median is 2.53 vs. the industry median of 2.78, Actinium Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.78, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Actinium Pharmaceuticals's current PB Ratio of 11.47 is 312.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Actinium Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Actinium Pharmaceuticals's current PB Ratio is 11.47, which is 353% above median its own 10-year median of 2.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actinium Pharmaceuticals stock overvalued right now?
Actinium Pharmaceuticals (STU:7AY1) has a current PB Ratio of 11.47. The current PB Ratio is 11.47, which is 353% above median its 10-year median of 2.53 and 312.6% above the Biotechnology industry median of 2.78. Actinium Pharmaceuticals' overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Actinium Pharmaceuticals (STU:7AY1), the current PB Ratio is 11.47 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
25GF Score
Get the complete analysis for STU:7AY1
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7AY1 has been successfully added to your 
